Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379936 | 0.90 | RAB9A (0.41) | — | |
| SCHEMBL4381102 | 0.82 | KDM4E (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4544242 | 0.80 | KDM4E (0.44) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4544065 | 0.78 | KDM4E (0.42) | CYP1A2 | |
| Dipyridyl SCHEMBL28135789 | 0.78 | KDM4E (0.64) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4379878 | 0.74 | KDM4E (0.52) | CYP1A2 | |
| SCHEMBL28204855 | 0.74 | RAB9A (0.58) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL11780094 | 0.73 | NAAA (0.43) | CES1 | |
| SCHEMBL6972295 | 0.73 | NAAA (0.43) | CES1 | |
| SCHEMBL11650441 | 0.72 | RAB9A (0.56) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084608-B2 | 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2128165-A1 | 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof | Shin-Etsu Chemical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299068-A1 | 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX | CBR3, TST, HRH3 | CYP1A2 339/4885CYP2D6 1023/4885CYP19A1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.